Related Experiment Video
Updated: Dec 6, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Observational study of people infected with SARS-Cov-2, treated with amantadine
Gonzalo Emiliano Aranda-Abreu1, José D Aranda-Martínez2, Ramiro Araújo3
1Universidad Veracruzana/Centro de Investigaciones Cerebrales, Xalapa, Veracruz, Mexico. garanda@uv.mx.
Background:
We conducted an observational study of 15 patients from a Southeastern area of Mexico with symptoms compatible with SARS-Cov-2, which were treated with the antiviral amantadine.
Methodology:
In this study, data were collected from 15 individuals with clinical symptoms of COVID-19 infection, which were treated on an ambulatory basis with 100 mg of amantadine for a period of 14 days.
Results:
This drug demonstrated its effectiveness, as patients recovered successfully with this treatment without the necessity of attending a hospital to use mechanical ventilation. All patients developed IgG antibodies to SARS-Cov-2.
Conclusion:
Amantadine can be used as a viable and cost-effective alternative for treating people with severe acute respiratory syndrome (SARS-Cov-2) on an ambulatory basis, while the vaccine is not available.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...